Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Camlin Fine Sciences Limited (CAMLINFINE.NS)
Mumbai, IN
Camlin Fine Sciences Limited, an India-based company headquartered in Mumbai and established in 1931 (originally as Camlin Fine Chemicals Limited until August 2011), is involved in the global research, development, production, and distribution of a diverse range of specialty chemicals, ingredients, and additive formulations. The company offers extensive shelf-life extension solutions under its Xtendra and NaSure brands. These include various antioxidants such as Tertiary Butyl Hydroquinone, Butylated Hydroxy Anisole, and Ascorbyl palmitate, alongside natural alternatives like mixed tocopherols, green tea extract, rosemary extract, and acerola extract. Additionally, its offerings comprise mold inhibitors, preservatives, acidifiers, antibacterial agents, toxin binders, pellet binders, and growth promoters. Its product line also features aroma ingredients, notably vanillin and ethyl vanillin, as well as nutraceuticals sourced through fermentation and plant extraction processes. Furthermore, Camlin Fine Sciences provides performance chemicals like hydroquinone and catechol, and a selection of downstream fine chemicals, including Guaiacol, Veratrole, TBC, MEHQ, and HQEE. These versatile products cater to numerous industries worldwide, encompassing food and beverage, pet food and animal nutrition, biodiesel, aquaculture, rendering, petrochemicals, agrochemicals, pharmaceuticals, polymers, dyes and pigments, biscuits and cookies, chocolate and confectionery, fragrance manufacturing, bakery, flavor, electroplating, and dietary supplements. The company actively engages in international exports of its goods.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.10% | +5.42% | +1.97% | -11.97% | -20.44% | -12.27% | -46.98% | -23.24% | -29.89% | +38.28% | +50.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+3.4% Q1'26: +2.6% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+118.3% ★ Q1'26: +11,173.2% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+0.6% Q1'26: +8.8% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+1.4% Q1'26: +0.1% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+1.6% Q1'26: +0.1% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+8.8% Q1'26: +10.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×7.55× Q1'26: 8.48× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.09B
est: 3.65B (+39.4%)
|
5.58B
est: 4.23B (+31.9%)
|
4.89B
est: 5.04B (-3.0%)
|
5.28B
est: 5.25B (+0.6%)
|
7.15B
est: 7.22B (-1.0%)
|
8.83B
est: 8.89B (-0.6%)
|
10.40B
est: 10.12B (+2.8%)
|
11.81B
est: 11.91B (-0.9%)
|
14.04B
est: 14.00B (+0.3%)
|
16.82B
est: 16.48B (+2.0%)
|
15.95B
est: 18.99B (-16.0%)
|
16.67B
est: 17.23B (-3.3%)
|
17.48B
17.05B – 17.91B
+1.4% YoY
|
19.68B
19.01B – 20.36B
+12.6% YoY
|
22.88B
21.98B – 23.78B
+16.2% YoY
|
| EBITDA |
655.38M
est: 397.64M (+64.8%)
|
874.13M
est: 461.16M (+89.6%)
|
862.76M
est: 401.97M (+114.6%)
|
407.10M
est: 506.17M (-19.6%)
|
235.76M
est: -214.98M (+209.7%)
|
735.13M
est: -372.68M (+297.3%)
|
1.18B
est: 260.27M (+354.1%)
|
1.89B
est: 639.38M (+195.5%)
|
1.79B
est: 783.22M (+128.8%)
|
1.84B
est: 897.44M (+105.0%)
|
487.60M
est: 1.06B (-54.2%)
|
1.95B
est: 1.88B (+4.0%)
|
1.90B
1.86B – 1.95B
+1.4% YoY
|
2.14B
2.07B – 2.22B
+12.6% YoY
|
2.49B
2.39B – 2.59B
+16.2% YoY
|
| EBIT |
537.52M
est: 250.10M (+114.9%)
|
711.67M
est: 290.05M (+145.4%)
|
692.21M
est: 600.74M (+15.2%)
|
189.08M
est: 751.45M (-74.8%)
|
-30.78M
est: 154.78M (-119.9%)
|
445.20M
est: -137.05M (+424.8%)
|
853.96M
est: 462.59M (+84.6%)
|
1.45B
est: 1.18B (+22.7%)
|
1.23B
est: 1.44B (-14.7%)
|
1.22B
est: 1.65B (-26.6%)
|
-298.47M
est: 1.96B (-115.2%)
|
1.31B
est: 1.18B (+11.3%)
|
1.20B
1.17B – 1.23B
+1.4% YoY
|
1.35B
1.30B – 1.40B
+12.6% YoY
|
1.57B
1.51B – 1.63B
+16.2% YoY
|
| Net Income |
287.13M
est: 406.68M (-29.4%)
|
550.27M
est: 437.51M (+25.8%)
|
358.24M
est: 456.49M (-21.5%)
|
-111.74M
est: 371.49M (-130.1%)
|
-296.43M
est: -153.56M (-93.0%)
|
5.77M
est: -364.99M (+101.6%)
|
303.19M
est: 6.56M (+4,518.3%)
|
509.63M
est: 365.08M (+39.6%)
|
606.78M
est: 447.21M (+35.7%)
|
521.06M
est: 512.43M (+1.7%)
|
-927.53M
est: 607.68M (-252.6%)
|
-1.39B
est: -82.33M (-1,588.9%)
|
846.80M
-16.94B – 18.63B
+1,128.6% YoY
|
1.92B
1.63B – 2.22B
+127.1% YoY
|
2.73B
2.62B – 2.85B
+42.2% YoY
|
| SGA |
—
est: 310.18M (-100.0%)
|
164.58M
est: 359.73M (-54.3%)
|
277.85M
est: 934.47M (-70.3%)
|
393.60M
est: 1.16B (-66.1%)
|
379.18M
est: 2.20B (-82.8%)
|
425.20M
est: 2.16B (-80.3%)
|
528.98M
est: 2.50B (-78.9%)
|
1.30B
est: 2.90B (-55.2%)
|
577.24M
est: 3.56B (-83.8%)
|
1.82B
est: 4.07B (-55.3%)
|
597.73M
est: 4.83B (-87.6%)
|
2.13B
est: 1.46B (+45.4%)
|
1.49B
1.45B – 1.52B
+1.4% YoY
|
1.67B
1.62B – 1.73B
+12.6% YoY
|
1.94B
1.87B – 2.02B
+16.2% YoY
|
| EPS |
3.06
est: 2.31 (+32.7%)
|
5.77
est: 2.48 (+132.7%)
|
3.73
est: 5.67 (-34.2%)
|
-1.26
est: 2.25 (-156.1%)
|
-3.07
est: -0.29 (-947.5%)
|
0.05
est: 2.30 (-97.9%)
|
2.50
est: 3.91 (-36.1%)
|
4.03
est: 7.23 (-44.3%)
|
4.54
est: 8.21 (-44.7%)
|
3.37
est: 6.42 (-47.5%)
|
-5.45
est: 10.45 (-152.1%)
|
-7.88
est: -0.47 (-1,588.6%)
|
4.80
-96.00 – 105.60
+1,128.6% YoY
|
10.90
9.21 – 12.59
+127.1% YoY
|
15.50
14.87 – 16.13
+42.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ashish Subhash Dandekar | Chairman & MD | 28M | male |
| Nirmal Vinod Momaya | MD & Director | 25M | male |
| Arjun Sudhakar Dukane | Executive Director of Technical & Executive Director | 12M | male |
| Rahul D. Sawale | Company Secretary, Compliance Officer & Vice President of Legal | 1M | male |
| Santosh L. Parab | Chief Financial Officer | — | male |
| Nilesh Jadhav | Chief Operating Officer | — | male |
| Raghunath Bal | Global Head of IT | — | — |
| Rajani Subhash Dandekar | Management Consultant | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CAMLINFINE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
